News and Updates

Breakthrough T1D has supported eye disease research since its beginning, and has driven discoveries that have reduced the risk of blindness by 95%.

Find out why we absolutely love psychologist Jill Weissberg-Benchell.

Leading researchers gathered, in person, for the annual meeting of the ATTD Conference (April 27-30), featuring 30+ studies presented by Breakthrough T1D scientists.

Vertex provides an update on their Phase 1/2 Clinical Trial for VX-880, including data from three participants and details around the clinical hold.

Diabetes researchers from all over the world gather for the ATTD Conference, which will take place in-person and online from April 27-30 in Barcelona.

You’ve seen the ads: Victoza®. Ozempic®. Trulicity®. But did you know that these drugs came about, in part, because of type 1 diabetes research?

In 1976, researchers set out to synthesize the human insulin gene and make human insulin, and Breakthrough T1D researchers had multiple hands in the biosynthesis of it.

In conjunction with leading partners, Breakthrough T1D lends its support to Civica, to help combat a nationwide insulin affordability crisis.

FDA approves Senseonics Eversense® E3, the first long-term implantable CGM system, and the E3 includes technology that extends the use for up to 6 months.

In 1974, a colony of non-diabetic BB rats develops diabetes. Examination of their pancreases revealed that they had no beta cells.